fludarabine IV / Generic mfg. - LARVOL DELTA

CB-011, an Allogeneic Anti-Bcma CAR-T Cell Therapy with Immune Cloaking, for Patients with Relapsed/Refractory Multiple Myeloma (Cammouflage Phase 1 Trial) (IMS 2026) - P1 | "Pts received lymphodepletion (LD) for 3 days with 300 mg/m 2 or 500 mg/m 2 of cyclophosphamide (cy) and 30 mg/m 2 of fludarabine, followed by a single infusion of CB-011 at doses of 50 million (M), 150M, 300M, 450M, or 800M CAR-T cells. In a high-risk, heavily pretreated r/r MM pt population, CB-011 drove deep and durable responses with a manageable safety profile. Based on these results, the RDE is 450M CB-011 CAR-T cells after 500 cy LD. The dose expansion phase of CaMMouflage is enrolling BCMA-naïve and prior BCMA therapy-exposed r/r MM patients."

CAR T-Cell Therapy • Clinical • P1 data • CNS Disorders • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Movement Disorders • Multiple Myeloma • Parkinson's Disease • Pneumonia • Rare Diseases • Respiratory Diseases • B2M • CD8 • HLA-E

First-in-Human Phase 1 Study of RD140, a Fully Human BCMA/GPRC5D Dual-Targeting FasT CAR-T, in Relapsed/Refractory Multiple Myeloma(RRMM) and Plasma Cell Leukemia(PCL) (IMS 2026) - P1 | "Following lymphodepletion with cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m 2 for three consecutive days, RD140 was administered as single infusion at 2 dose levels (DL) of 1x10 5 cells/kg (DL1, n = 3) or 3x10 5 cells/kg (DL2, n=6). The current data demonstrated that BCMA/GPRC5D dual-targeting FasT CAR-T RD140 provide deep responses and a very high MRD negativity rate with a favorable safety profile, including in RRMM pts exposed to anti-CD38, PI and IMiDs. Further evaluation in a larger patient population with longer follow-up is warranted."

CAR T-Cell Therapy • First-in-human • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - P2 | N=45 | Active, not recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Dec 2028 ➔ Aug 2027 | Trial primary completion date: Dec 2028 ➔ Aug 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Burkitt Lymphoma • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Mast Cell Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • HLA-B • HLA-C • HLA-DRB1

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial. (PubMed, Blood) - P3 | "The phase 3 CRISTALLO trial (NCT04285567) compared first-line fixed-duration venetoclax-obinutuzumab (VenO) vs fludarabine, cyclophosphamide, and rituximab (FCR)/bendamustine-rituximab (BR) in patients with chronic lymphocytic leukemia, using undetectable minimal residual disease (uMRD) as the sole primary endpoint. No patient in the VenO arm was deemed high-risk for tumor lysis syndrome following obinutuzumab debulking; no clinical TLS occurred. These results confirm and extend the findings from the GAIA-CLL13 trial, validating increased depth of response with VenO vs chemoimmunotherapies."

IO biomarker • Journal • P3 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • TP53

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (PubMed, N Engl J Med) - P3 | "Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.)."

Clinical • IO biomarker • Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • IGH • TP53

IMPACT OF SEX ON EFFICACY, TOLERABILITY AND PATIENT-REPORTED OUTCOMES IN FIRST-LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE CLL13/GAIA STUDY (EHA 2026) - "Background Venetoclax (V) and obinutuzumab (GA101, G), with or without ibrutinib (I), has demonstrated superiority over chemoimmunotherapy (C) with fludarabine, cyclophosphamide (FC) and rituximab (R) or R-Bendamustine as first-line treatment in fit patients (pts) with chronic lymphocytic leukemia (CLL). These findings suggest that sex may influence treatment tolerability, depth of remission and pts experience in CLL, warranting further investigation regarding treatment optimization according to sex. Figure 1 shows a) progression free survival and b) overall survival according to sex in patients treated with chemoimmunotherapy, rituximab and venetoclax, obinutuzumab and venetoclax as well as obinutzumab, venetoclax and ibrutinib as first-line treatment in chronic lymphocytic leukemia."

Clinical • Patient reported outcomes • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Richter's Syndrome • TP53

An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada. (PubMed, Clin Lymphoma Myeloma Leuk) - "These results highlight the shift in the treatment landscape for CLL with the potential for improved patient outcomes."

Journal • Observational data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "With more than 4 years of follow-up, venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib significantly extended progression-free survival compared with both chemoimmunotherapy and venetoclax-rituximab in previously untreated, fit patients with chronic lymphocytic leukaemia, thereby supporting their use and further evaluation in this patient group, while still considering the higher toxicities observed with the triple combination."

Clinical • Journal • P3 data • P3 data • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lung Cancer • Neutropenia • Oncology • Richter's Syndrome • Septic Shock • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • TP53

Early Experience With Glofitamab Plus Polatuzumab Vedotin as Bridging Therapy Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma (SOHO 2026) - "Cycle 1: obinutuzumab (1000 mg) or rituximab (375 mg/m2) day 1, Pola (1.8 mg/kg) day 2, Glofit (2.5 mg) day 8 and (10 mg) day 15 in a 21-day cycle...After fludarabine-cyclophosphamide, a single Tali-cel infusion of ≥5 × 106 cells/kg was given... Glofit-Pola BT in R/R LBCL achieved high responses and enabled 93% to proceed to CAR-T therapy. Responses were largely maintained post Tali-cel. BT: bridging therapy, CAR-T: chimeric antigen receptor T-cell therapy, CI: confidence interval, CR: complete response, CRS: cytokine release syndrome, Glofit-Pola: glofitamab and polatuzumab vedotin, ICANS: immune effector cell–associated neurotoxicity syndrome, ICU: intensive care unit, LDH: lactate dehydrogenase, ORR: objective response rate, OS: overall survival, PD: progressive disease, PFS: progression-free survival, R/R LBCL: relapsed/refractory large B-cell lymphoma, SD: stable disease, Tali-cel: talicabtagene autoleucel."

CAR T-Cell Therapy • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial (ASH 2025) - "The CRISTALLO Phase III trial comparedthe efficacy and safety of fixed duration (FD) VenO vs fludarabine-cyclophosphamide-rituximab/bendamustine-rituximab (FCR/BR) in fit pts with treatment (Tx)-naïve CLL (Sharman et al. CRISTALLO demonstrated that FD VenO causes differential effects on malignant and non-malignant B-cell populations, with sustained CLL cell depletion in pts achieving uMRD alongside B-cellrecovery, delayed T-cell recovery and effective Ig reconstitution. Findings extend previous observationsand confirm that immune reconstitution can occur while maintaining deep remissions. Furthermore, finalanalysis results continue to support the efficacy and safety of FD VenO."

Clinical • P3 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • CD24 • CD8 • FCER2 • NCAM1

Risk of Therapy-Related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Retrospective Multicenter Analysis Using the TriNetX Database (SOHO 2026) - "Adult patients with CLL treated with ibrutinib, acalabrutinib, or zanubrutinib were included. Patients with prior chemoimmunotherapy exposure, including fludarabine/cyclophosphamide, FCR, bendamustine/rituximab, and obinutuzumab/chlorambucil, were excluded to better isolate the long-term effects of BTKi therapy... In this large real-world TriNetX analysis of patients with CLL treated with BTK inhibitors and without prior chemoimmunotherapy exposure, therapy-related myeloid neoplasms were uncommon but increased over longer follow-up. MDS was the most frequent secondary myeloid neoplasm, followed by AML. The underlying immune dysregulation inherent to CLL, including impaired immune surveillance and defective T-cell function, may also contribute to the development of secondary malignancies in this population."

Retrospective data • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Oncology

MAINTENANCE OF HEALTH-RELATED QUALITY OF LIFE WITH VENETOCLAX-OBINUTUZUMAB VS CHEMOIMMUNOTHERAPY IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE PHASE 3 CRISTALLO TRIAL (EHA 2026) - P3 | "The Phase 3 CRISTALLO trial (NCT04285567) compared the efficacy and safety of fixed-duration chemotherapy- free venetoclax-obinutuzumab (VenO) vs fludarabine-cyclophosphamide-rituximab/bendamustine-rituximab (FCR/BR) in fit pts with treatment-naïve CLL without del(17p) or TP53 mutations. The lack of significant symptom interference compared with standard chemoimmunotherapy underscores the value of VenO as a patient-centric treatment that preserves HRQoL. Together with the PROs reported in the CLL14 trial and previously reported clinical outcomes, these results support the value of VenO, a fixed-duration and chemotherapy-free regimen, for fit pts with treatment-naïve CLL."

Clinical • HEOR • IO biomarker • P3 data • Chronic Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Insomnia • Leukemia • Sleep Disorder • TP53

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial (ASH 2024) - P3 | "Patients were randomized 1 : 1 : 1 to receive acalabrutinib-venetoclax (AV; oral acalabrutinib 100 mg BID [cycles 1–14]; oral venetoclax QD [cycles 3–14 with 5-week dose ramp-up [20, 50, 100, 200, 400 mg]), acalabrutinib-venetoclax-obinutuzumab (AVO; AV dosing as above, plus intravenous obinutuzumab 1000 mg cycles 2 [days 1, 8, and 15] and 3−7 [day 1]), or investigator's choice of fludarabine-cyclophosphamide-rituximab (FCR) or bendamustine-rituximab (BR) per standard dosing protocol (cycles 1−6). Conclusions : AMPLIFY met its primary endpoint, demonstrating superior BICR-assessed PFS with AV vs FCR/BR, with similar findings seen with AVO vs FCR/BR. The combinations of AV and AVO provided deep and durable responses with manageable safety profiles, with AV offering the first all-oral fixed-duration regimen that combines venetoclax with a second-generation BTKi in fit patients with TN CLL."

Clinical • IO biomarker • P3 data • P3 data: top line • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Neutropenia • Oncology • IGH • TP53

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (ASH 2024) - P2 | "Standard lymphodepleting chemotherapy with fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 will be given, followed by Axi-cel infusion. Glofitamab step-up dosing will be repeated in cycle 3 without re-treatment with obinutuzumab...The sample size of 40 patients will allow for 80% power at the significance level of 0.05 to determine if the historical response rate of 0.65 is different from the projected experimental response rate of 0.825. Exploratory analyses are planned to evaluate the tumor profile and antigen density, single cell multiome sequencing and whole exome sequencing, ctDNA kinetics, and immune cell fitness."

Clinical • P2 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study (ASH 2023) - P, P2 | "Whereas fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy (CIT) had a median progression-free survival (mPFS) of 11.2 months and median overall survival (mOS) of 33.1 months as frontline therapy in del17p CLL (Fisher et al...In a similar patient subset, the CLL14 study demonstrated a mPFS of 51.9 months and a 5-year OS of 60.0% using fixed-duration venetoclax and obinutuzumab (Al-Sawaf et al... These results further define the long-term prognosis of patients treated with BTK inhibitors for CLL, most notably with substantial improvements in the OS of patients with TP53 alterations over CIT. Additionally, these results may inform discussions of continuous BTK inhibitor therapy versus fixed-duration venetoclax combinations in frontline therapy of high-risk CLL. In a subset of ibrutinib-treated patients, depth of response increased over multiple years to the point of uMRD suggesting the possibility that such patients might safely discontinue therapy,..."

IO biomarker • P2 data • Alzheimer's Disease • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • CNS Disorders • Dementia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Respiratory Diseases • IGH • TP53

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. (PubMed, N Engl J Med) - P3 | "Venetoclax-obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA-CLL13 ClinicalTrials.gov number, NCT02950051; EudraCT number, 2015-004936-36.)."

Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • TP53

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=51 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Suspended ➔ Active, not recruiting

Enrollment closed • Platinum resistant • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • TACSTD2

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • KRAS

INITIAL RESULTS OF THE LUMINICE-203 STUDY INVESTIGATING ACIMTAMIG WITH OFF-THE-SHELF ALLOGENEIC NATURAL KILLER CELLS (ALLONK®) IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (EBMT 2025) - P2 | "Background: Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who progress following chemotherapy, brentuximab vedotin (BV) and PD-1 inhibitors require novel treatment options...After lymphodepletion treatment with fludarabine/cyclophosphamide (Days −5 to −3) AlloNK and acimtamig are co-administered on Days 1, 8, and 15, followed by acimtamig only on Days 22, 29 and 36 of a 58-day cycle, for up to 3 cycles... Acimtamig plus AlloNK exhibits promising efficacy and tolerability in heavily pretreated patients. Combining acimtamig with a scalable, off-the-shelf NK-cell product has the potential to address a high unmet need in patients with R/R cHL who otherwise have no SOC option. The study is ongoing"

Classical Hodgkin Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Oncology • FCGR3A • TNFRSF8

Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma (ASH 2022) - P1/2 | "Patients aged 15–75 years with R/R CD30+ lymphomas refractory to brentuximab vedotin are enrolled...Each treatment cycle consisted of fludarabine/cyclophosphamide (days −5 to −3), followed by infusion of the AFM13-NK cells, cultured for 14 days as described above (day 0), and three weekly IV infusions of AFM13 (200 mg, days 7, 14 and 21)... This is the first clinical trial to date using an ICE® construct precomplexed with cytokine-induced memory-like CB-NK cells to treat patients with CD30+ R/R HL and NHL. Our preliminary results indicate that this ICE® precomplexed CB-NK cell therapy has an excellent tolerability profile and is highly active in patients with heavily pretreated R/R CD30+ lymphomas and warrants further investigation."

Clinical • IO biomarker • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • FCGR3A • IL12A • IL15 • IL18 • IL21 • TNFRSF8

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study (ASH 2024) - P1/2, P2 | "Introduction : Patients (pts) with R/R cHL are in need of new treatment options, especially after failure of standard treatments including brentuximab vedotin (BV) and PD-1 inhibitors...After a standard lymphodepletion treatment regimen with fludarabine/cyclophosphamide (Days -5 to -3) pts receive AlloN- and acimtamig coadministered on days 1,8,15 followed by acimtamig only on days 22,29 and 36 of a 48-day cycle for up to 3 cycles...These early results are in line with previous data from study NCT04074746 which used fresh allogeneic NK cells thereby validating the co-administration approach of acimtamig with an off-the-shelf, allogeneic, cryopreserved NK cell product (AlloNK) in R/R cHL. This treatment has the potential to address a high unmet need in R/R cHL pts who have otherwise no SOC option."

P2 data • Classical Hodgkin Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Oncology • FCGR3A • TNFRSF8

Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Ruijin Hospital

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22

Long-Term Survival and Associated Idiopathic Pneumonia Syndrome (IPS) Outcomes Following Total Body Irradiation (TBI)-Conditioned Hematopoietic Stem Cell Transplantation (HSCT) for Acute Leukemia (ASTRO 2026) - "Pretransplant conditioning consisted of cyclophosphamide with fludarabine in 69% of patients and cyclophosphamide alone in 31%. At 10-year follow-up, while a subset of patients developed IPS associated with TBI-conditioned HSCT, there was no statistically significant difference in 10-year mortality between patients with and without IPS, and deaths from IPS represented a small share of total mortality. We conclude that in a large cohort of patients with acute leukemia, patients with TBI-HSCT associated IPS did not have statistically inferior overall survival relative to those without IPS."

Hematological Malignancies • Leukemia • Oncology

Ring Gantry Linear Accelerator Based Total Lymphoid Irradiation (TLI) Based Myeloablative Conditioning Regimen in Hematopoietic Stem Cell Transplant (HSCT) in Thalassemia: A Single Institute Experience (ASTRO 2026) - "Materials/ This is a single centre retrospective study of children who underwent hematopoietic stem cell transplantation (HSCT) using a uniform conditioning with single fraction TLI, Antithymocyte globulin, Cyclophosphamide, Fludarabine, Treosulfan and Thiotepa. TLI-based conditioning demonstrates a favorable tolerability, limited treatment related toxicity and should be included in haploidentical HSCT to ensure engraftment will full donor chimerism in children with TDT Thalassaemia."

Breast Cancer • Hematological Malignancies • Oncology • Solid Tumor

a and ß Emitting Radiopharmaceutical Therapy (RPT) and Total Marrow and Lymphoid Irradiation (TMLI) Conditioning in Relapsed / Refractory (R/R) AML / ALL Undergoing Allogeneic Transplant (alloHCT) (ASTRO 2026) - P1 | "In R/R acute leukemia patients undergoing alloHCT, TMLI 12 Gy, fludarabine (F), and melphalan (M) resulted in a promising 5-year overall survival of 42%...Trial 2 NCT06287944: Same study design except alpha-emitting 225Ac-anti-CD38 Daratumumab was used... Combining a or ß emitting RPT with 12 Gy TMLI /F/M appears feasible with no DLTs observed to date. Combined radiation doses to organs from RPT and TMLI were lower compared to 12 Gy TBI. Using RPT in a combined modality approach, in a radiosensitive disease and in a potentially curative setting warrants further evaluation."

Acute Myelogenous Leukemia • Oncology